Vir Biotechnology, Inc. (NASDAQ:VIR) CEO Sells $474,286.40 in Stock

Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CEO Backer Marianne De sold 79,712 shares of Vir Biotechnology stock in a transaction dated Thursday, April 3rd. The shares were sold at an average price of $5.95, for a total transaction of $474,286.40. Following the sale, the chief executive officer now directly owns 769,505 shares in the company, valued at $4,578,554.75. The trade was a 9.39 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Vir Biotechnology Stock Performance

Shares of Vir Biotechnology stock traded up $0.53 on Wednesday, hitting $5.72. 2,531,058 shares of the company's stock were exchanged, compared to its average volume of 1,335,355. Vir Biotechnology, Inc. has a 1 year low of $4.95 and a 1 year high of $14.45. The company has a 50-day simple moving average of $7.86 and a 200-day simple moving average of $8.21. The stock has a market capitalization of $784.46 million, a PE ratio of -1.46 and a beta of 1.14.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.76) EPS for the quarter, topping analysts' consensus estimates of ($0.85) by $0.09. The company had revenue of $12.37 million for the quarter, compared to analysts' expectations of $8.14 million. Vir Biotechnology had a negative net margin of 678.40% and a negative return on equity of 36.71%. On average, analysts expect that Vir Biotechnology, Inc. will post -3.92 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently weighed in on VIR shares. Morgan Stanley raised Vir Biotechnology from an "equal weight" rating to an "overweight" rating and raised their price objective for the company from $10.00 to $20.00 in a research report on Thursday, January 9th. JPMorgan Chase & Co. lifted their price target on Vir Biotechnology from $10.00 to $14.00 and gave the stock a "neutral" rating in a research report on Thursday, January 9th. Needham & Company LLC reissued a "buy" rating and set a $19.00 price objective on shares of Vir Biotechnology in a research report on Thursday, February 27th. Barclays upped their target price on shares of Vir Biotechnology from $26.00 to $31.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. Finally, Leerink Partners raised their price target on shares of Vir Biotechnology from $18.00 to $20.00 and gave the company an "outperform" rating in a research report on Monday, January 13th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $35.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VIR. State of Tennessee Department of Treasury raised its stake in shares of Vir Biotechnology by 3.2% in the fourth quarter. State of Tennessee Department of Treasury now owns 39,268 shares of the company's stock valued at $288,000 after acquiring an additional 1,227 shares during the period. Rhumbline Advisers increased its stake in Vir Biotechnology by 0.5% in the fourth quarter. Rhumbline Advisers now owns 236,681 shares of the company's stock worth $1,737,000 after purchasing an additional 1,288 shares during the period. PNC Financial Services Group Inc. increased its stake in Vir Biotechnology by 31.8% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,288 shares of the company's stock worth $61,000 after purchasing an additional 1,999 shares during the period. Teacher Retirement System of Texas lifted its position in shares of Vir Biotechnology by 10.7% during the fourth quarter. Teacher Retirement System of Texas now owns 26,440 shares of the company's stock worth $194,000 after purchasing an additional 2,556 shares during the last quarter. Finally, Invesco Ltd. boosted its stake in shares of Vir Biotechnology by 0.6% during the fourth quarter. Invesco Ltd. now owns 398,772 shares of the company's stock valued at $2,927,000 after purchasing an additional 2,574 shares during the period. Hedge funds and other institutional investors own 65.32% of the company's stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).